Gumboro disease, also called infectious bursal disease (IBD), is a viral disease caused by infectious bursal disease virus (IBDV), which primarily targets the immune system of chickens. This disease is widely prevalent among turkeys and ducks who have not been induced with immunosuppression. Gumboro disease is a highly contagious disease occurring in chickens older than 3 weeks of age. The disease is associated with various symptoms such as staining of feathers around the vent with feces and several urates, ruffled feathers, anorexia dehydration in the pectoral, thigh, and abdominal muscles, as well as impaired kidneys by chronic urate diathesis. Subclinical infection results in deficiency in immunological response to infectious Bronchitis, Newcastle disease, Marek’s disease, as well as increase susceptibility to gangrenous dermatitis and Inclusion Body Hepatitis. Supplement of multivitamin and facilitating access to water might help in curing the disease, as no medical treatment for this disease has been developed.
High transmission rate of gumboro disease and rising need to prevent it, are the important factors contributing to the growth of gumboro disease market
Increasing prevalence rate of Gumboro disease is affecting the poultry industry drastically. This is a contiguous disease and it is easy to transmit through all the poultry area, as infected chickens sheds the infection in their feces resulting in to the loss of poultry business. Treatment requirement for Gumboro disease to reduce loss is driving the growth of Gumboro disease market. According to the data published by Science Alert in 2013, economic loss due to Gumboro disease in Nigeria for 2009, 2010, and 2011 accounted for more than 3 billion Nigerian currency. According to the data published by Centre d’etudes et de Recherché, Belgium in 2000, the mortality rate due to Gumboro disease in the U.S. was 5% whereas in Japan and Europe the rate is high 50% to 60% in laying hens and 25% to 30% in broilers.
However, increase in research and developments with new vaccines in the pipeline for the prevention from Gumboro disease is expected to propel the Gumboro disease market. For instance, the Transmune IBD vaccines available by CEVA manufacturers has proven effective for Gumboro disease.
New vaccine development and their effective results are accounting for the larger share of vaccine segment in gumboro disease market
The global gumboro disease market is segmented by species type, by vaccines type and by region
On the basis of species type, the Gumboro Disease Market is segmented into:
On the basis of vaccines type, the Gumboro disease market is segmented into:
High rate of chicken consumers in North America is the driving factor for gumboro disease market in this region
Regional segmentation of Gumboro Disease Market by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the major share in the Gumboro disease market due to the high prevalence of gumboro disease and increasing investment in the research and development. The U.S. is the largest broiler chicken industry in the world. According to National Chicken Council, in 2015, there was around 9 billion production of broiler chicken in the U.S. The chicken consumers are more in this region than any other regions in world, so the chances of poultry industry getting affected by Gumboro disease and loss caused by it is more in America, which is driving the growth of gumboro disease market in North America.
Rapid development in the field of vaccinology and novel biotechnology tools are helping the industry players to progress in the gumboro disease market
Key industry players operating the Gumboro Disease Market includes Ceva, ROMVAC Company SA, PTSanbe Farma, Jiangyin Caina Technology co. limited, Cios Co., Salfarm Danmark A/s., Vetbiochem, and others. Growing research and development in the vaccine technology field and increase in rate of gumboro disease is encouraging the vaccine manufacturers to invest in gumboro disease market. Rapid development in the area of immunology, animal science, and biotechnology is giving rise to new biotechnology tools for helping the industry players to sustain in the gumboro disease market.
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Select a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients